Michael Thomas Henderson
CIK 1779990 · Chief Executive Officer · last filed 2026-09-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
APGE price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
PALO ALTO, CA 94301
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Apogee Therapeutics, Inc. (APGE) Delisted | Chief Executive Officer | 0 | $135.07 | $0 | -$37.96M | 26 | 2026-09-03 |
| SYRE | Director | 68,606 | $92.91 | $6.37M | -$7.95M | 7 | 2026-06-23 |
| ARYA Sciences Acquisition Corp IV (ARYD) Delisted | Director | — | $6.64 | — | $0 | 1 | 2024-07-31 |
| BBIO | Chief Business Officer | 274,211 | $68.15 | $18.69M | -$3.64M | 22 | 2020-12-17 |
Recent Filings · Page 5 of 8
71 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-09-06 | Apogee Therapeutics, Inc. (APGE) Delisted | Sell (S) | −40,000 | -$1.90M | EDGAR |
| 2024-09-04 | Apogee Therapeutics, Inc. (APGE) Delisted | Notice (144) | −40,000 | -$1.90M | EDGAR |
| 2024-08-09 | Apogee Therapeutics, Inc. (APGE) Delisted | Sell (S) | −40,000 | -$1.62M | EDGAR |
| 2024-08-07 | Apogee Therapeutics, Inc. (APGE) Delisted | Notice (144) | −40,000 | -$1.62M | EDGAR |
| 2024-07-31 | ARYA Sciences Acquisition Corp IV (ARYD) Delisted | Disp (D) | — | $0 | EDGAR |
| 2024-07-05 | Apogee Therapeutics, Inc. (APGE) Delisted | Sell (S) | −15,000 | -$558.9K | EDGAR |
| 2024-07-05 | Apogee Therapeutics, Inc. (APGE) Delisted | Notice (144) | −15,000 | -$558.9K | EDGAR |
| 2024-05-16 | SYRE | Grant (A) | — | $0 | EDGAR |
| 2023-12-20 | Apogee Therapeutics, Inc. (APGE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-12-17 | BBIO | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.